arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Avalo Therapeutics, Inc.

AVTX
$18.34 ▼ -0.42 (-2.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
50 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Avalo Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $368.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -30.6%
FCF / Share $-0.88
Trailing P/E
Price / Book 6.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$59.00K
↓ -69.3%
Net Income Profit after all expenses
$-19.63M
↓ -49.3%
Operating Margin Operating profit as % of sales
27.4%
↑ +141.4%
FCF / Share Free cash flow per share
$-0.88
↑ +2.2%
Long-Term Debt Long-term obligations
$14.25M
— -0.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 50 quarters